Nigral Dopaminergic Neurons is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Nigral dopaminergic neurons are located in the substantia nigra pars compacta (SNpc) and are the primary neurons lost in Parkinson's disease. These neurons project to the striatum forming the nigrostriatal pathway, which is essential for motor control and reward processing[1].
The SNpc contains approximately 400,000-600,000 dopaminergic neurons in a healthy human brain, representing only about 1% of the total neuronal population but accounting for a large proportion of the brain's dopamine content[2].
The substantia nigra is divided into two main regions:
Nigral dopaminergic neurons are characterized by:
These neurons project primarily to the dorsal striatum (caudate nucleus and putamen), forming the nigrostriatal pathway[3]. This pathway is critical for:
The selective vulnerability of nigral dopaminergic neurons is a hallmark of Parkinson's disease, with 50-70% of these neurons lost by the time clinical symptoms appear[4].
Key mechanisms include:
Why these specific neurons are vulnerable remains an active research area. Contributing factors include[6]:
The study of Nigral Dopaminergic Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015;386(9996):896-912. DOI:10.1016/S0140-6736(1461393-3 ↩︎
Cheng HC, Ulane CM, Burke RE. Clinical progression in Parkinson disease and the neurobiology of axons. Ann Neurol. 2010;67(6):715-725. DOI:10.1002/ana.21911 ↩︎
Björklund A, Dunnett SB. Dopamine neuron systems in the brain: an update. Trends Neurosci. 2007;30(5):194-202. DOI:10.1016/j.tins.2007.03.006 ↩︎
Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain. 1991;114(Pt 5):2283-2301. DOI:10.1093/brain/114.5.2283 ↩︎
Spillantini MG, Schmidt ML, Lee VM, et al. Alpha-synuclein in Lewy bodies. Nature. 1997;388(6645):839-840. DOI:10.1038/42166 ↩︎
Surmeier DJ, Guzman JN, Sanchez J, Schumacker PT. Physiological phenotype and vulnerability in Parkinson's disease. Cold Spring Harb Perspect Med. 2012;2(9):a009380. DOI:10.1101/cshperspect.a009380 ↩︎
Mittermeyer G, Christine CW, Rosenbluth KH, et al. Long-term evaluation of AAV2-AADC gene therapy for Parkinson's disease. Mol Ther. 2012;20(4):729-735. DOI:10.1038/mt.2011.287 ↩︎